Reports
Sale
Global Protease Inhibitors Market Growth, Shre, Size, Forecast: By Disease Indication: HIV/ AIDS, Hepatitis C, Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema (HAE), Others; By Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online; Regional Analysis; Competitive Landscape; Industry Events and Developments; 2024-2032
Global Protease Inhibitors Market Outlook
The global protease inhibitors market is expected to grow at a CAGR of 4.30% in the forecast period of 2024-2032 driven by the increasing prevalence of viral diseases such as HIV/AIDS and hepatitis C.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Key Trends in the Market
Protein slicing or cutting enzymes are known as proteases. The function of protease is inhibited by protease inhibitor, which stops the viral replication. The molecules known as protease inhibitors have numerous uses. In some circumstances, the term protease inhibitor (PI) refers to a particular class of medication that is predominantly used to treat HIV/AIDS and hepatitis. In addition to antiviral medications, these protease inhibitors can be utilised to treat diabetes and cancer. For protein purification or cell/tissue extraction, a variety of protease inhibitors can be utilised as reagents.
- The protease inhibitors market is anticipated to grow significantly during the forecast period. The creation of pharmaceutical protease inhibitors that target a particular protease enzyme is of great interest. Thus, it is anticipated that the market will expand during the forecast period as a result of the rising prevalence of viral disorders including HIV/AIDS and hepatitis C.
- Another important element driving the expansion of the global market for protease inhibitors is the growing public awareness of anti-retroviral therapy and new forms of cancer treatment.
- The development of the protease inhibitors market is anticipated to be fuelled by increasing research and development (R&D) activities in the fields of animal tissue culture, protein purification, pharmacology, and molecular biology.
- Additionally, an increase in the number of pharmaceutical manufacturers, incidence of lifestyle illnesses, and approval of protease inhibitors medications will likely propel the market growth during the forecast period.
Global Protease Inhibitors Market Analysis
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on disease indication, the market is segmented into HIV/ AIDS, hepatitis C, alpha-1 antitrypsin deficiency, and hereditary angioedema (HAE), among others. The market, on the basis of distribution channels is categorised into hospital pharmacies, retail pharmacies, and online. The regional markets for protease inhibitors can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global protease inhibitors market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.
- Thermo Fisher Scientific
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Johnson & Johnson Services, Inc.
- KalVista Pharmaceuticals, Inc.
- Others
Market Share by Disease Indication
HIV/AIDS are growing in prevalence worldwide, and with no cure, effective treatments are highly in demand. Protease inhibitors are a class of antiretroviral medication used to treat HIV, resulting in the HIV/AIDS disease indication dominating the protease inhibitors market growth.
Protease inhibitors aim to lower the body's viral load—a measure of the amount of the HIV virus—to undetectable levels. Drugs called protease inhibitors stop the activity of protease enzymes. This stops the HIV life cycle by preventing protease enzymes from playing their function in enabling HIV to proliferate.
Use of protease inhibitors helps treat the symptoms of HIV, inhibit the spread of the virus, and prevent it from replicating. To properly treat HIV, protease inhibitors must be taken with other drugs. Almost all protease inhibitors require the addition of either ritonavir or cobicistat in order to be fully effective.
Market Share by Region
North America is anticipated to lead the global market for protease inhibitors during the forecast period. This can be attributed to factors including the region's high prevalence of HIV and chronic hepatitis C virus, and effective healthcare infrastructure that are anticipated to propel the market in North America.
The market in the Asia Pacific region is anticipated to expand at a fast rate during the forecast period due to factors like a high prevalence of chronic diseases, ageing population, and the growing concentration of pharmaceutical companies in Asia Pacific. Additionally, a rise in awareness of anti-retroviral drugs across continents like Asia is stimulating the global protease inhibitors market.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
Thermo Fisher Scientific, a provider of scientific equipment, reagents and consumables, and software services, is based in the United States. The 1956-founded business provides goods and services that benefit clients all over the world in hospitals and laboratories, on assembly lines, and in the field. It generates around USD 40 billion in annual revenue and is a driving force in the research, healthcare, industrial, and application markets.
Boehringer Ingelheim International GmbH, a German-based pharmaceutical business creates, produces, and sells medicines, parasiticides, vaccines, and treatments for unmet medical needs. It provides a wide range of products, including biopharmaceuticals, animal health care items, and treatments for human ailments. The company's goods are used, among other things, to treat diseases of the immune system, central neurological system, cardiometabolic system, respiratory system, retina, and various cancers.
Bristol-Myers Squibb Company, a speciality biopharmaceutical company founded in 1887 with its headquarters in the United States, specialises in the discovery, development, licencing, manufacturing, marketing, distribution, and sale of medications and other healthcare products to patients with serious diseases. Its main areas of focus are cardiovascular, cancer, immunology, and fibrotic therapeutic projects. The business provides its goods to wholesalers, retail pharmacies, hospitals, healthcare workers, and governmental organisations all around the world.
Other market players include Johnson & Johnson Services, Inc. and KalVista Pharmaceuticals, Inc., among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Indication |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Protease Inhibitors Market Analysis
8.1 Key Industry Highlights
8.2 Global Protease Inhibitors Historical Market (2018-2023)
8.3 Global Protease Inhibitors Market Forecast (2024-2032)
8.4 Global Protease Inhibitors Market by Disease Indication
8.4.1 HIV/ AIDS
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2023)
8.4.1.3 Forecast Trend (2024-2032)
8.4.2 Hepatitis C
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2023)
8.4.2.3 Forecast Trend (2024-2032)
8.4.3 Alpha-1 Antitrypsin Deficiency
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2023)
8.4.3.3 Forecast Trend (2024-2032)
8.4.4 Hereditary Angioedema (HAE)
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2018-2023)
8.4.4.3 Forecast Trend (2024-2032)
8.4.5 Others
8.5 Global Protease Inhibitors Market by Distribution Channels
8.5.1 Hospital Pharmacies
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2023)
8.5.1.3 Forecast Trend (2024-2032)
8.5.2 Retail Pharmacies
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2023)
8.5.2.3 Forecast Trend (2024-2032)
8.5.3 Online
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2023)
8.5.3.3 Forecast Trend (2024-2032)
8.6 Global Protease Inhibitors Market by Region
8.6.1 Market Share
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Latin America
8.6.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2023)
9.3.2 Forecast Trend (2024-2032)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2018-2023)
9.4.2 Forecast Trend (2024-2032)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2023)
9.5.2 Forecast Trend (2024-2032)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 Thermo Fisher Scientific
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 Boehringer Ingelheim International GmbH
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 Bristol-Myers Squibb Company
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 Johnson & Johnson Services, Inc.
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 KalVista Pharmaceuticals, Inc.
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 Others
12 Industry Events and Developments
List of Key Figures and Tables
1. Global Protease Inhibitors Market: Key Industry Highlights, 2018 and 2032
2. Global Protease Inhibitors Historical Market: Breakup by Disease Indication (USD Million), 2018-2023
3. Global Protease Inhibitors Market Forecast: Breakup by Disease Indication (USD Million), 2024-2032
4. Global Protease Inhibitors Historical Market: Breakup by Distribution Channels (USD Million), 2018-2023
5. Global Protease Inhibitors Market Forecast: Breakup by Distribution Channels (USD Million), 2024-2032
6. Global Protease Inhibitors Historical Market: Breakup by Region (USD Million), 2018-2023
7. Global Protease Inhibitors Market Forecast: Breakup by Region (USD Million), 2024-2032
8. North America Protease Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
9. North America Protease Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
10. Europe Protease Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
11. Europe Protease Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
12. Asia Pacific Protease Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
13. Asia Pacific Protease Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Latin America Protease Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
15. Latin America Protease Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Middle East and Africa Protease Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
17. Middle East and Africa Protease Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
18. Global Protease Inhibitors Market Structure
Key Questions Answered in the Report
The market for protease inhibitors is projected to grow at a CAGR of 4.30% between 2024 and 2032.
The major drivers of the protease inhibitors market include the rising prevalence of viral disorders including HIV/AIDS and hepatitis C and the growing public awareness of anti-retroviral therapy and cancer treatment.
The extensive research and development efforts, increase in the number of pharmaceutical manufacturers, increase in the incidence of lifestyle illnesses, approval of protease inhibitors (PI) medications, efficient health care infrastructure, and a growing ageing population are the key industry trends propelling the growth of the market.
The major players in the industry are Thermo Fisher Scientific, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., and KalVista Pharmaceuticals, Inc., among others.
Tubers and plant seeds are abundant with protease inhibitors. Although significant levels of proteinase inhibitors are frequently seen in many plants belonging to the Solanaceae family, proteinase inhibitors are present in plants from a number of systematic groups.
The protease inhibitors approved by the United States Food and Drug Administration (FDA) include: saquinavir mesylate (Invirase), tipranavir (Aptivus), darunavir ethanolate (Prezista), atazanavir sulfate (Reyataz), fosamprenavir calcium (Lexiva), indinavir sulfate (Crixivan), ritonavir (Norvir), and nelfinavir mesylate (Viracept).
Protease inhibitors are specifically antiviral medications that are used to treat targeted viruses such as HIV (human immunodeficiency virus).
Protease inhibitors are utilised to protect protein samples from the proteases' digestive activity, which begins during the isolation procedure. They are used in order to avoid imminent spontaneous breakdown of protein samples and cell lysates.
Some of the common diseases are treated with protease inhibitors are HIV/ AIDS, hepatitis C, alpha-1 antitrypsin deficiency, and hereditary angioedema (HAE), among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER